WASHINGTON, June 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2023, to be held in Indianapolis, IN from June 3 – 7, 2023. The following will be presented:
Presentation Title: "Melanopsin Genetic Variants and Delayed Sleep Phenotype – Whole Genome Sequencing Analysis" Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Poster Session Presentation Time: 5:00 PM – 6:00 PM ET
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Poster Session Presentation Time: 12:00 PM – 1:15 PM ET
Presentation Title: "Effect of Iloperidone on Sleep Symptoms in Bipolar Patients with Manic and Mixed Episodes: A Randomized, Placebo Controlled Study" Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Poster Session Presentation Time: 5:00 PM – 6:00 PM ET
For more information on SLEEP 2023, please refer to https://www.sleepmeeting.org/.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma. Senior Vice President, Chief Financial Officer and Treasurer
Head of Corporate Affairs